CD4 and tuberculosis: Among tuberculosis patients who survived at least 6 months from the time of tuberculosis diagnosis, receipt of > 6 months of anti-tuberculosis therapy was associated with a significantly decreased risk of death after adjusting for CD4+ lymphocyte count and HIV-1 RNA at the time of tuberculosis diagnosis, as well as timing of ART initiation in relation to anti-tuberculosis therapy initiation (HR 0.23; 95% CI 0.08, 0.66; P=0.007; Table 4).